Clinical practice gaps around infection prevention are getting clearer for advanced cell and antibody therapies. An international survey covering 101 medical institutions found substantial variation in infection prophylaxis and surveillance for patients receiving bispecific antibodies and CAR-T cell therapies, underscoring inconsistent standards for preventing opportunistic and treatment-related infections. The survey highlights where operational protocols diverge even as these regimens become more widely used.
Get the Daily Brief